4884 Stock Overview
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kringle Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥564.00 |
| 52 Week High | JP¥1,037.00 |
| 52 Week Low | JP¥394.00 |
| Beta | 0.52 |
| 1 Month Change | 8.25% |
| 3 Month Change | -25.89% |
| 1 Year Change | -41.19% |
| 3 Year Change | -39.09% |
| 5 Year Change | n/a |
| Change since IPO | -53.12% |
Recent News & Updates
Shareholder Returns
| 4884 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -3.3% | -6.2% | -3.0% |
| 1Y | -41.2% | -30.3% | 27.6% |
Return vs Industry: 4884 underperformed the JP Biotechs industry which returned -30.3% over the past year.
Return vs Market: 4884 underperformed the JP Market which returned 27.6% over the past year.
Price Volatility
| 4884 volatility | |
|---|---|
| 4884 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 8.2% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4884's share price has been volatile over the past 3 months.
Volatility Over Time: 4884's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 13 | Kiichi Adachi | www.kringle-pharma.com |
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.
Kringle Pharma, Inc. Fundamentals Summary
| 4884 fundamental statistics | |
|---|---|
| Market cap | JP¥3.69b |
| Earnings (TTM) | -JP¥866.00m |
| Revenue (TTM) | JP¥70.00m |
52.5x
P/S Ratio-4.2x
P/E RatioIs 4884 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4884 income statement (TTM) | |
|---|---|
| Revenue | JP¥70.00m |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥70.00m |
| Other Expenses | JP¥936.00m |
| Earnings | -JP¥866.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | -133.00 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,237.14% |
| Debt/Equity Ratio | 0% |
How did 4884 perform over the long term?
See historical performance and comparison